Alemtuzumab induces severe orbitopathy in relapsing–remitting multiple sclerosis-Reference-Cited by-同舟云学术

Alemtuzumab induces severe orbitopathy in relapsing–remitting multiple sclerosis

Published:2023-09-29 Issue:1 Volume:271 Page:486-496
ISSN:0340-5354
Container-title:Journal of Neurology
language:en
Short-container-title:J Neurol

Author:

Rodríguez de Vera Gómez Pablo^ORCID,Méndez Muros Mariola,Torres Cuadro Alberto,Toyos Sáenz de Miera Francisco Javier,López Ruiz Rocío,Guerrero Vázquez Raquel,García González Juan Jesús,Garrido Hermosilla Antonio Manuel,Martín Hernández Tomás

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

https://link.springer.com/content/pdf/10.1007/s00415-023-11995-6.pdf

Reference35 articles.

1. Katsavos S, Coles A (2018) Alemtuzumab as treatment for multiple sclerosis. Cold Spring Harb Perspect Med 8(10):a032029. https://doi.org/10.1101/cshperspect.a032029

2. Meca-Lallana J, Fernández-Prada M, García Vázquez E et al (2022) Consensus statement on the use of Alemtuzumab in daily clinical practice in Spain. Neurologia (Engl Ed). 37(8):615–630. https://doi.org/10.1016/j.nrleng.2019.11.001

3. Daniels GH, Vladic A, Brinar V et al (2014) Alemtuzumab related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J Clin Endocrinol Metab 99:80–89. https://doi.org/10.1210/jc.2013-2201

4. Fox EJ, Sullivan HC, Gazda SK et al (2012) A single-arm, open-label study of Alemtuzumab in treatment refractory patients with multiple sclerosis. Eur J Neurol 19(2):307–311. https://doi.org/10.1111/j.1468-1331.2011.03507.x

5. European Medicines Agency (2020) Measures to minimize risk of serious side effects of multiple sclerosis medicine Lemtrada. https://www.ema.europa.eu/en/medicines/human/referrals/lemtrada. Accessed 26 Sept 2023

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alemtuzumab;Reactions Weekly;2024-04-06

2. Alemtuzumab-induced thyroid eye disease successfully treated with a single low-dose of rituximab;European Thyroid Journal;2024-03